Shawn Jobe, MD
Pediatric Hematology-Oncology · Lansing, MINPI 1801005855
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $66,384 of the $93,955 with a category attached, or 70.7%. It is spread thinly across 14 manufacturers, the largest accounting for just 21.3%. Reporting peaked in 2019 at $29,018 and has fallen 93.2% since, to $1,975 in 2025. Among pediatric hematology-oncology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 97 payments — averaging $968.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bioverativ Therapeutics Inc.$20K
- Sanofi$20K
- Octapharma USA, Inc.$15K
- Takeda Pharmaceuticals U.S.A., Inc.$11K
- Shire North American Group Inc$7K
- Spark Therapeutics, Inc.$7K
- plus $15K from 8 others
Across 135 payments — averaging $942.96 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- CSL Behring$54K
- Novo Nordisk AS$25K
- Genentech, Inc.$15K
- Sanofi US Services Inc.$14K
- Bioverativ Therapeutics Inc.$9K
- Pfizer$8K
- plus $2K from 2 others
What the payments were for
- Consulting fees$66,38471%
- Speaking & faculty fees$17,51919%
- Travel & lodging$7,2958%
- Food & beverage$2,7043%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bioverativ Therapeutics Inc. | 14 | $20,007 |
| Sanofi | 3 | $19,699 |
| Octapharma USA, Inc. | 39 | $14,661 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $10,729 |
| Shire North American Group Inc | 13 | $7,020 |
| Spark Therapeutics, Inc. | 5 | $6,858 |
| CSL Behring | 4 | $6,058 |
| Genentech USA, Inc. | 6 | $6,010 |
| Kedrion Biopharma Inc. | 2 | $2,734 |
| Bayer | 1 | $78 |
| Agios Pharmaceuticals, Inc. | 1 | $36 |
| Novo Nordisk | 1 | $32 |
| Tempus AI, Inc | 1 | $17 |
| HEMA Biologics, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$93,955 in reported general payments places this provider in the 90th percentile of 84 pediatric hematology-oncology providers in Michigan.
See all pediatric hematology-oncology providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pediatric hematology-oncology in Lansing
- Roshni KulkarniLansing$149K
- Renuka GeraLansing$859
- David CerviLansing$155
- Steven PipeAnn Arbor$1.3M
- Angela WeyandAnn Arbor$384K
- Michael CallaghanDetroit$374K
- Jordan ShavitAnn Arbor$190K
- Ahmar ZaidiDetroit$119K
- Troy QuiggGrand Rapids$101K
- Andrew CampbellAnn Arbor$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.